Showing results (41-50 of 757) with videos related to

Sort By:
Pageof 76
Saudi Journal of Kidney Diseases and Transplantation : an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia|January 23, 2008
Mechanisms of progression of chronic renal diseaseRoberto Pisoni, Claudio Aros, Piero Ruggenenti, et al.
Kidney International|April 5, 2003
Predicting end-stage renal disease: Bayesian perspective of information transfer in the clinical decision-making process at the individual levelBorislav D Dimitrov, Annalisa Perna, Piero Ruggenenti, et al.
BMJ Case Reports|January 26, 2020
Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sicknessManuel Alfredo Podestà, Barbara Ruggiero, Giuseppe Remuzzi, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 19, 2007
Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathyPaolo Cravedi, Piero Ruggenenti, Maria Chiara Sghirlanzoni, et al.
Journal of Renal Care|July 1, 2010
The diabetic CKD patient--a major cardiovascular challengeIrene M van der Meer, Piero Ruggenenti, Giuseppe Remuzzi
Nature Reviews. Nephrology|April 2, 2022
Glomerular hyperfiltrationMonica Cortinovis, Norberto Perico, Piero Ruggenenti, et al.
Pediatric Nephrology (Berlin, Germany)|October 6, 2016
Achieving remission of proteinuria in childhood CKDPiero Ruggenenti, Paolo Cravedi, Antonietta Chianca, et al.
Current Diabetes Reviews|March 29, 2011
Prevention and treatment of diabetic retinopathy: evidence from clinical trials and perspectivesManuela Abbate, Paolo Cravedi, Ilian Iliev, et al.
Pharmaceuticals (Basel, Switzerland)|October 8, 2016
Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?Paolo Cravedi, Varusca Brusegan, Piero Ruggenenti, et al.
Journal of the American Society of Nephrology : JASN|November 4, 2006
Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trialPiero Ruggenenti, Annalisa Perna, Maria Ganeva, et al.
Pageof 76